Literature DB >> 29213225

Role of blue dye for sentinel lymph node detection in early endometrial cancer.

Stefano Restaino1, Carlo Ronsini2, Angelo Finelli2, Emanuele Perrone3, Giovanni Scambia3, Francesco Fanfani2.   

Abstract

BACKGROUND: Sentinel Lymphonode analysis has become a barely new and innovative way to treat early stages of endometrial cancer (Ballester et al., Lancet Oncol 469-476, 2011; Buda et al., Ann Surg Oncol 2975-81, 2016). Indocyanine green cervical injection is considered gold standard for mapping nodes' drainage. Blue dye is used as a valid alternative in many centers, due to the lower cost of execution. The objective of this video is to prove that methylene blue dye's cervical injection is a valid and "low-cost" method to obtain mapping of lymphatic drainage in patient with early endometrial cancer.
METHODS: Fifty-four-year old women, with a recent diagnosis of endometrial cancer IA G2, we performed a radical Hysterectomy type A. We diluted in equal proportions the blue dye and saline and injected 1 cl in depth and 1 cl on the surface of the cervix, at 3 o'clock and 9 o'clock. After 20 min, it was shown with precision the lymphatic drainage until the first lymph node station from both sides.
RESULTS: One external iliac lymph node and one obturator were resected on the left side and one external iliac on the right side. On histological analysis, none of the lymph nodes had any location of metastasis, neither micro-metastasis. Myometrial infiltration was 8/19 mm.
CONCLUSIONS: Blue dye cervical injection is a "low-cost", safe, and satisfactory procedure to point out Sentinel Lymph Node of uterus drainage. Other tracers, such as indocyanine green, are widely used in gynecological oncology, but with a higher cost of the product and the needing of a dedicated optical filter to be shown on human view.

Entities:  

Keywords:  Blue dye; Endometrial cancer; Lymph node

Year:  2017        PMID: 29213225      PMCID: PMC5707225          DOI: 10.1186/s10397-017-1026-0

Source DB:  PubMed          Journal:  Gynecol Surg        ISSN: 1613-2076


Background

Sentinel lymph node analysis has become a new and innovative method to treat early stages of endometrial cancer [1, 2]. In the aim of reducing complications related to lymphoadenectomy, the use of different tracers to identify first lymph node absorber of the drainage chain is widely propagated in gynecological oncology centers. Indocyanine green cervical injection is considered gold standard for mapping nodes’ drainage, but this technique requires a dedicated optical filter to catch signal. Blue dye is used as a valid alternative (77 Vs 97% bilateral detection rate) in many centers, due to the minor cost of performing. The objective of this video is to prove that methylene blue dye’s cervical injection is a valid and low-cost method to obtain mapping of lymphatic drainage in patient with early endometrial cancer.

Methods

In a 54-year-old woman, BMI 28, with a recent diagnosis of Endometrial Cancer G2, with no previous imaging suspect of deep myometrial infiltration (> 50%), we performed a radical hysterectomy (class A of Querleu-Morrow’s classification), with bilateral salpingo-oophorectomy. Furthermore, we decided to act cervical injection of blue dye to identify the first lymph node station. We diluted in equal proportions the blue dye and saline and injected 1 cl in depth and 1 cl on the surface of the cervix, at 3 o’clock and 9 o’clock, in order to obtain a precise mapping of the lymphatic course. As in this case, we prefer to practice injection with a spinal anesthesia needle (27G), for the accurate ratio between length and cross section, which makes easier the deep and shallow injection without encountering excessive resistances. Injection of the cervix represents a crucial moment of this method. During this step, indeed, an excess pressure can determine an extravasation of the dye, which would color the entire parametrial space, making it impossible to identify the actual absorber structures. After 20 min, by accessing the retroperitoneum to parametrial level, it was shown with precision the lymphatic course until the first lymph node station from both sides. The lymph nodes had a clear accumulation of tracer, which facilitated the identification even in the absence of appropriate optical filters (Additional file 1).

Results

One external iliac lymph node and one obturator were resected on the left side and one external iliac on the right side. On histological analysis, none of the lymph nodes had any location of metastasis, neither micro-metastasis. Myometrial infiltration was 8/19 mm. Operation time, including cervical injection, was 47 min, and no abnormal bleedings were reported. Patient was discharged the day after.

Conclusion

In our experience, blue dye cervical injection is a “low-cost”, safe, and satisfactory procedure to point out sentinel lymph node of uterus drainage. This could help to avoid an overtreatment such as a systematic pelvic lymphadenectomy in patient which have a diagnosis of uterine malignancy. Other tracers, such as indocyanine green, are widely used in gynecological oncology, but with a higher cost of the product and the needing of a dedicated optical filter to be shown on human view. The recent FIRES study demonstrates that indocyanine green cervical injection has a high degree of diagnostic accuracy in patients with endometrial cancer [3]. Is not in the aim of this case report to prove which is the best tracer for endometrial sentinel lymph node, but it is to prove the feasibility of the method with blue dye, a more “comfortable” product.
  3 in total

1.  A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.

Authors:  Emma C Rossi; Lynn D Kowalski; Jennifer Scalici; Leigh Cantrell; Kevin Schuler; Rabbie K Hanna; Michael Method; Melissa Ade; Anastasia Ivanova; John F Boggess
Journal:  Lancet Oncol       Date:  2017-02-01       Impact factor: 41.316

2.  Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO).

Authors:  Marcos Ballester; Gil Dubernard; Fabrice Lécuru; Denis Heitz; Patrice Mathevet; Henri Marret; Denis Querleu; François Golfier; Eric Leblanc; Roman Rouzier; Emile Daraï
Journal:  Lancet Oncol       Date:  2011-04-12       Impact factor: 41.316

3.  Quality of Care for Cervical and Endometrial Cancer Patients: The Impact of Different Techniques of Sentinel Lymph Node Mapping on Patient Satisfaction.

Authors:  Alessandro Buda; Federica Elisei; Sharon Palazzi; Elena De Ponti; Maurizio Arosio; Francesca Vecchione; Tiziana Dell'Anna; Marco Cuzzocrea; Beatrice Bussi; Daniela Giuliani; Giampaolo Di Martino; Cinzia Crivellaro
Journal:  Ann Surg Oncol       Date:  2016-04-26       Impact factor: 5.344

  3 in total
  5 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

Review 2.  Fertility-Sparing Treatment for Early-Stage Cervical Cancer ≥ 2 cm: A Problem with a Thousand Nuances-A Systematic Review of Oncological Outcomes.

Authors:  Carlo Ronsini; Maria Cristina Solazzo; Nicolò Bizzarri; Domenico Ambrosio; Marco La Verde; Marco Torella; Raffaela Maria Carotenuto; Luigi Cobellis; Nicola Colacurci; Pasquale De Franciscis
Journal:  Ann Surg Oncol       Date:  2022-09-05       Impact factor: 4.339

3.  Step-by-step surgical procedures for a correct identification of the sentinel lymph node in endometrial cancer.

Authors:  S Restaino; A Finelli; A Lucidi; A Ercoli; G Scambia; F Fanfani
Journal:  Facts Views Vis Obgyn       Date:  2021-01-08

4.  Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer.

Authors:  Carlo Ronsini; Lavinia Mosca; Irene Iavarone; Roberta Nicoletti; Davide Vinci; Raffaela Maria Carotenuto; Francesca Pasanisi; Maria Cristina Solazzo; Pasquale De Franciscis; Marco Torella; Marco La Verde; Nicola Colacurci; Luigi Cobellis; Giuseppe Vizzielli; Stefano Restaino
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

5.  Dye diffusion during laparoscopic tubal patency tests may suggest a lymphatic contribution to dissemination in endometriosis: A prospective, observational study.

Authors:  Marco Scioscia; Anna Pesci; Arnaldo Scardapane; Marco Noventa; Gloria Bonaccorsi; Pantaleo Greco; Giuseppe Zamboni
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.